Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -209.84M | -15.84M | -16.59M | -18.50M | -21.44M |
| Total Depreciation and Amortization | 34.00K | -27.00K | 23.00K | 91.00K | 181.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 184.72M | 2.76M | 3.35M | 4.16M | 5.30M |
| Change in Net Operating Assets | 18.36M | 879.00K | -46.00K | -882.00K | -2.67M |
| Cash from Operations | -6.73M | -12.23M | -13.26M | -15.13M | -18.62M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -17.37M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 6.00M | 11.65M |
| Cash from Investing | -17.37M | 0.00 | 0.00 | 6.00M | 11.65M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 33.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 266.81M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 266.84M | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 705.00K | 156.00K | 612.00K | -26.00K | -317.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 243.45M | -12.07M | -12.65M | -9.15M | -7.29M |